PMID: 11932066Apr 5, 2002Paper

TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics

Pain
Prisca HonoreMichael F Jarvis

Abstract

Exogenous ATP has been shown to be algogenic in both animal and humans. Research has focused on the P2X3 ligand-gated ion channel, as it is preferentially expressed on nociceptive C-fibers. In addition, P2X3 receptor gene disrupted mice show decreased responses to somatic painful stimuli. However, the potential role of P2X receptor activation in visceral pain has not yet been evaluated. In the present study, the systemic administration of suramin, and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid, PPADS, both non-selective P2X receptor antagonists, dose-dependently reduced acetic acid-induced abdominal constrictions in mice (ED(50)=34.5 micromol/kg and ED50=70 micromol/kg, respectively). Furthermore, 2'-(or-3')-O-(trinitrophenyl)adenosine 5'- tri-phosphate (TNP-ATP) potently (IC50=10 nM) blocked the functional activation of P2X3 receptors in vitro and attenuated acetic acid-induced visceral pain. In the abdominal constriction assay, TNP-ATP (ED(50)=6.35 micromol/kg, i.p.) was 6-10 fold more potent than suramin and PPADS to reduce nociceptive behavior. In addition, TNP-ATP was 10 fold more potent than TNP-AMP (2'-(or-3')-O-(trinitrophenyl)adenosine 5'-mono-phosphate) (ED50=63.5 micromol/kg, i.p.) at reducing acetic acid-...Continue Reading

References

Mar 17, 1987·European Journal of Pharmacology·M Nakamura, S H Ferreira
Feb 1, 1968·British Journal of Pharmacology and Chemotherapy·H O CollierC Schneider
Aug 25, 1983·Nature·C E Jahr, T M Jessell
Nov 1, 1993·British Journal of Pharmacology·S H FerreiraS Poole
Aug 1, 1997·British Journal of Pharmacology·B F KingG Burnstock
Oct 6, 1997·British Journal of Pharmacology·P A Bland-Ward, P P Humphrey
Aug 27, 1998·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·A R SantosG A De Freitas
Mar 17, 1999·British Journal of Pharmacology·S UenoK Inoue
Aug 10, 1999·European Journal of Pharmacology·B R BianchiT van Biesen
Sep 14, 1999·Journal of Neurophysiology·E C BurgardM F Jarvis
Nov 11, 1999·British Journal of Pharmacology·B F KingG Burnstock
May 24, 2000·British Journal of Anaesthesia·G Burnstock

❮ Previous
Next ❯

Citations

May 2, 2006·Pflügers Archiv : European journal of physiology·Joel R GeverAnthony P D W Ford
Oct 24, 2007·Molecular Neurobiology·Kerstin WirknerPeter Illes
Dec 4, 2003·Current Opinion in Pharmacology·Peter Holzer
Nov 13, 2003·Peptides·Richard J Bodnar, Maria M Hadjimarkou
Jan 25, 2005·Nature Medicine·Vera JankowskiJoachim Jankowski
Feb 24, 2011·The Journal of Biological Chemistry·Amulya Nidhi ShrivastavaIsabella Sarto-Jackson
Sep 10, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Daniel N WillisJohn B Morris
May 12, 2010·Acta Physiologica·P Holzer
Jun 24, 2004·Canadian Journal of Physiology and Pharmacology·H F MirandaG Pinardi
Mar 24, 2011·Future Medicinal Chemistry·Elena ColomboPaolo Pevarello
Oct 3, 2014·BioMed Research International·Giulia Magni, Stefania Ceruti
Jun 27, 2003·Anesthesiology·Philip M LangPeter Grafe
Aug 1, 2006·Expert Opinion on Therapeutic Patents·Char-Chang ShiehRichard J Perner
Jul 2, 2003·The Journal of Physiology·R Alan North
Apr 10, 2012·The Journal of Pain : Official Journal of the American Pain Society·Yi YeBrian L Schmidt
Nov 17, 2009·Trends in Neurosciences·Michael F Jarvis
Mar 22, 2005·British Journal of Pharmacology·Brian F KingGeoffrey Burnstock
Oct 29, 2003·British Journal of Pharmacology·Valeria SpeltaR Alan North
Aug 5, 2006·Alimentary Pharmacology & Therapeutics·R J Saad, W D Chey
Feb 9, 2006·British Journal of Pharmacology·Anthony P D W FordDebra A Cockayne
Mar 31, 2004·Brain Research·Soon Yong ParkJin-Ho Song
Oct 18, 2005·Pharmacology & Therapeutics·Geoffrey Burnstock
Jul 30, 2003·Expert Opinion on Therapeutic Targets·Michael F Jarvis
Apr 23, 2004·Expert Opinion on Therapeutic Targets·Peter Holzer
Nov 20, 2013·European Journal of Medicinal Chemistry·Joong-Heui ChoYong-Chul Kim
Oct 15, 2013·Pharmacology, Biochemistry, and Behavior·Suzy KrimonCarlos Amílcar Parada
Jul 29, 2008·Neuropharmacology·Michael F Jarvis, Baljit S Khakh
Sep 29, 2011·Experimental Neurology·Kazuhide Inoue, Makoto Tsuda
Mar 26, 2013·European Journal of Pharmacology·Geoffrey Burnstock
Apr 24, 2007·Pain·Margarita SuardíazFernando Rodríguez de Fonseca
Dec 2, 2009·Molecular Pain·Geoffrey Burnstock
Mar 23, 2017·ACS Chemical Neuroscience·Young-Hwan JungYong-Chul Kim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.